However, aspirin use in older adults not tied to incidence of various cancer types
WEDNESDAY, Jan. 27, 2021 (HealthDay News) — Aspirin use may improve survival for bladder and breast cancer, according to a study published online Jan. 15 in JAMA Network Open.
Holli A. Loomans-Kropp, Ph.D., M.P.H., from the National Cancer Institute in Rockville, Maryland, and colleagues investigated the association of aspirin use with the risk for developing new cancers, as well as site-specific cancer-associated survival for bladder, breast, esophageal, gastric, pancreatic, and uterine cancers. The analysis included 139,896 individuals (mean age, 66.4 years) participating in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (1993 to 2001).
The researchers found that aspirin use was not associated with the incidence of any studied cancer type. Aspirin use at least three times/week was associated with increased survival among patients with bladder (hazard ratio, 0.67) and breast (hazard ratio, 0.75) cancers. However, there was no survival benefit with esophageal, gastric, pancreatic, or uterine cancer. A similar association for bladder and breast cancer was seen for any aspirin use (hazard ratios, 0.75 and 0.79, respectively).
“The results presented here add to the accumulating evidence that aspirin may improve survival for some cancers,” the authors write.
.jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Gap Found Between Awareness of Breast Cancer Risk and Risk-Reducing Behavior 
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers 
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer 
Pre-Prostate Biopsy MRI Use Increased From 2017 to 2026 
ASTRO Issues Guidance for Use of Radiation Therapy in Bladder Cancer .jpeg)
Higher Intake of Saturated, Animal Fats May Increase Mortality in Prostate Cancer 
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer 
